Your browser doesn't support javascript.
loading
Esketamine clinical trials: reply to Maju et al.
Gastaldon, C; Papola, D; Ostuzzi, G; Barbui, C.
Affiliation
  • Gastaldon C; Department of Neuroscience, Biomedicine and Movement Sciences, Section of Psychiatry, University of Verona, Verona, Italy.
  • Papola D; Department of Neuroscience, Biomedicine and Movement Sciences, Section of Psychiatry, University of Verona, Verona, Italy.
  • Ostuzzi G; Department of Neuroscience, Biomedicine and Movement Sciences, Section of Psychiatry, University of Verona, Verona, Italy.
  • Barbui C; Department of Neuroscience, Biomedicine and Movement Sciences, Section of Psychiatry, University of Verona, Verona, Italy.
Epidemiol Psychiatr Sci ; 29: e122, 2020 Apr 29.
Article in En | MEDLINE | ID: mdl-32345395
Maju et al. provided clarifications on important and controversial issues related to esketamine clinical trial data, in response to a vivid debate triggered by the marketing authorisation recently granted by this new medicine. In this commentary, we reply to their comments attempting to critically discuss the evidence base needed to obtain regulatory approval.
Subject(s)
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Depressive Disorder, Treatment-Resistant / Ketamine / Antidepressive Agents Type of study: Clinical_trials Limits: Humans Country/Region as subject: America do norte Language: En Journal: Epidemiol Psychiatr Sci Year: 2020 Document type: Article Affiliation country: Italy Country of publication: United kingdom

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Depressive Disorder, Treatment-Resistant / Ketamine / Antidepressive Agents Type of study: Clinical_trials Limits: Humans Country/Region as subject: America do norte Language: En Journal: Epidemiol Psychiatr Sci Year: 2020 Document type: Article Affiliation country: Italy Country of publication: United kingdom